PSA Screening Overdiagnosis Rises Sharply With Age

Published Date: 02 May 2026

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Read Full News

Latest News

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

Todays Updates

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Todays Updates

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Latest News

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

News All Time

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Which Risk Model Better Identifies High-Risk Smoldering MM?

A cohort study compares the distribution and progression risk among individuals classified as having high-risk smoldering multiple myeloma by the AQUILA trial inclusion criteria vs 2/20/20 risk model.

EMA Recommends Generic in Advanced/Metastatic Breast Cancer

Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.

ICIs Show High Responses in Mediastinal B-Cell Lymphoma

Pembrolizumab and nivolumab show favorable response rates with or without consolidation therapy.

‘Bar Code’ Biopsy From RNA Could Guide Precision Oncology

New research shows how certain orphan noncoding RNA — oncRNA — can be predictable enough to be a ‘bar code’ identifying specific cancers. Liquid biopsy could be next.

CAR-T Induces Deep, Durable Remission in Smoldering Myeloma

In a pilot study — the first to test CAR-T therapy in smoldering multiple myeloma — patients with high-risk disease remained MRD-negative for more than 15 months. But is it a cure?

CD39 Blockade Shows Potential in Early-Stage Lung Cancer

A single-arm study hints at an uptick in pathologic complete responses when a CD39 blocker is added to perioperative durvalumab and chemotherapy for NSCLC.

Dasatinib Fails to Improve Outcomes in CBF-AML

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Measurable Residual Disease Predicts Real-World AML Relapse

A study of a real-world population underscores measurable residual disease thresholds indicative of the risk for relapse in NPM1-mutated AML, suggesting guidance in treatment decisions.

Can Oncotype Predict Recurrence Risk in Older BC Patients?

A recent study assesses whether Oncotype DX can predict local recurrence risk in older, lower-risk patients with breast cancer who omit adjuvant radiation.

Is Vitamin D a Key to Better Breast Cancer Survival?

A prospective study links sufficient vitamin D levels at the time of breast cancer diagnosis to improved overall survival.

Where Does Mistletoe Extract Fit in Supportive Cancer Care?

Mistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.

A Chemo-Free Option for Some Advanced Endometrial Cancers?

A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.

Early Tislelizumab May Boost PFS in Esophageal Cancer

For patients with locally advanced esophageal cancer, front-loading immunotherapy with induction chemo and chemoradiotherapy, without maintenance immunotherapy, may improve outcomes.

ctDNA Predicts Relapse in Locally Advanced Cervical Cancer

Posttreatment ctDNA positivity correlates with worse relapse-free survival and earlier recurrence in patients with locally advanced cervical cancer, real-world data show.

GLP-1 RAs May Lower Hysterectomy Risk in Endometrial Cancer

There’s now a hint that GLP-1 receptor agonists might prevent hysterectomies in endometrial intraepithelial neoplasia/early-stage endometrial cancer, but prospective trials are needed to confirm it.

Recommended News For You

Unlocking the potential of targeted therapies for multiple myeloma

Combination of significant weight gain and late motherhood greatly increases risk of breast cancer, study finds

Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

Prior authorizations draining time, energy from many cancer patients

PSA Screening Overdiagnosis Rises Sharply With Age

Study sheds light on challenges for women of color after breast cancer surgery

Recommended Articles For You

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer 

The Benefits and Risks of Thrombolytics: A Comprehensive Guide  

How Bispecific Antibodies are Redefining Medical Oncology in the US - A 2025 Review 

Expanding Oncology Frontiers: Rare Cancers, Breakthroughs, and Precision Medicine Advances 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

On all CAR-T products, the FDA is calling for a new boxed warning.

2.

A study has developed molecular markers that predict meningioma recurrence.

3.

Brexpiprazole Safe, Effective in Early-Episode Schizophrenia

4.

AI can identify women at risk of breast cancer years in advance: Study

5.

Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?

1.

A Visual Journey Through Penile Cancer: Examining the Impact of Photos

2.

Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy

3.

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment

4.

The Growing Crisis of Aplastic Anemia: A Call for Action

5.

Interpreting Iron Studies: What Your Blood Results Really Mean 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

2.

The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift

3.

INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients

4.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

5.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot